A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT06192875
Status
Recruiting
Apply to this trial

Conditions

  • Hematopoietic and Lymphoid System Neoplasm
  • Malignant Solid Neoplasm

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Non-Interventional Study — OTHER
    Non-interventional study

Study Details

This study is being done to establish "normal' values for a new blood test and urine test approach to cancer screening. Patients undergo blood and urine sample collection on study. Patients' medical records are reviewed.

Key Dates

Start date
Sep 28, 2015
Status verified
Mar 2026
Primary completion
Dec 31, 2035
Completion
Dec 31, 2035

Study Design

Enrollment
10,000 participants (estimated)

Arms

  • Arm: Observational
    Patients undergo blood and urine sample collection on study. Patients' medical records are reviewed.

Primary Outcome Measure

Blood level distributions of methylated DNA tumor markers [ Time Frame: Baseline ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic in RochesterRochesterMinnesota55905
Ellie Omerdic
[email protected]
507-266-1874
Clinical Trials Referral Office
[email protected]
855-776-0015
John B. Kisiel, M.D. (PRINCIPAL_INVESTIGATOR)

Find similar trials in Rochester, MN

By research site
Mayo Clinic in Rochester· Rochester, MN

Related Studies